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Abstract
Background: Perioral	 dermatitis	 is	 a	 clinically	 distinctive	 reaction	pattern	of	 facial	
dermatitis,	 including	 redness,	dryness,	burning,	pruritus	and	skin	 tightness.	A	gold	
standard	treatment	remains	unclear.
Objectives: Our	study	evaluates	the	clinical	value	of	a	skin	care	cream	with	the	tran‐
sient	receptor	potential	vanilloid	type	1	inhibitor	4‐t‐butylcyclohexanol	in	POD	pa‐
tients	over	8	weeks.
Methods: This	 open,	 unblinded	 8‐week	 clinical	 trial	 included	 48	 patients.	 A	 skin	
care	cream	containing	4‐t‐butylcyclohexanol	was	applied	over	a	period	of	8	weeks.	
Standardized	questionnaires	were	used	at	baseline,	4	and	8	weeks,	for	history	docu‐
mentation,	objective	and	subjective	severity	scores,	and	quality	of	life	assessments.	
Six	different	skin	physiology	parameters	were	assessed	at	all	timepoints.
Results: The	 perioral	 dermatitis	 severity	 score	 decreased	 significantly	 during	 the	
treatment	period.	This	was	mirrored	by	significantly	 lower	patients’	subjective	nu‐
merical	rating	score	and	an	improved	quality	of	life	score.	Transepidermal	water	loss,	
stratum	 corneum	 hydration	 and	 skin	 erythema	 improved	 significantly	 during	 the	
treatment	period.
Conclusion: This	 transient	 receptor	 potential	 vanilloid	 type	 1	 inhibitor‐based	 skin	
care	 cream	 improved	 subjective	 and	 objective	 parameters	 of	 perioral	 dermatitis.	
Decreased	transepidermal	water	loss	values	and	increased	stratum	corneum	hydra‐
tion	demonstrate	a	restored	skin	barrier	function.	Consequently,	the	topical	inhibi‐
tion	of	these	receptors	is	a	promising	management	option	for	POD.
K E Y W O R D S
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1  | INTRODUC TION
Perioral	dermatitis	(POD)	first	described	in	1964	by	Mihan	and	Ayres	
is	a	clinically	characteristic	skin	reaction	pattern	typically	affecting	the	
perioral	 area	and	 the	perinasal/periocular	areas	with	erythema	and	
papules.1	Patients	are	mostly	women	aged	between	15	and	45	years	
and	complain	about	skin	tightness	and	burning	sensation	more	than	
about	pruritus.	POD	runs	a	chronic	course	due	to	treatment	failure	or	
noncompliance,	leading	to	a	substantial	psychological	burden.2
Hypotheses	raised	to	explain	the	pathogenesis	of	POD	suggest	
that	this	condition	is	the	result	of	a	vicious	circle	consisting	of	ex‐
cessive	skin	care,	disruption	of	the	barrier	function,	and	an	increase	
in	transepidermal	water	loss	(TEWL),	which	leads	to	subjective	skin	
dryness,	resulting	in	the	patient	overusing	moisturizers.	Additionally,	
many	patients	are	known	to	be	atopic.	The	intermittent	use	of	po‐
tent	topical	steroids	is	an	established	risk	factor	for	POD.3,4
POD	treatment	is	mainly	based	on	clinical	experience,	and	there	
is	 one	published	guideline	on	POD	management.5	Zero	 therapy	 is	
an	established	approach,	but	the	low	patient	compliance	is	further	
reduced	by	an	initial	exacerbation.	Two	randomized,	double‐blinded,	
placebo‐controlled	clinical	trials	with	pimecrolimus	cream	have	been	
published.6,7	Several	other,	less	well‐controlled	studies	have	evalu‐
ated	topical	metronidazole	and	erythromycin,	as	well	as	some	sys‐
temic	antibiotics.5	The	clinical	value	of	twice	daily	application	of	a	
drug‐free	cosmetic	fluid	has	also	been	reported.8
As	 none	 of	 the	 known	 treatment	 options	 seems	 optimal,	 and	
the	 role	of	 inhibiting	TRPV1	 receptors	 in	 treating	 sensitive	 skin	 is	
already	established,9	we	decided	to	evaluate	a	skin	care	cream	with	
the	TRPV1‐inhibitor	4‐t‐butylcyclohexanol	to	improve	the	objective	
parameters	and	subjective	symptoms	of	POD.
2  | MATERIAL S AND METHODS
2.1 | Study design
Our	trial	was	a	single‐center,	open‐label,	unblinded,	8‐week	study.	
Inclusion	criteria	for	our	study	were	adult	patients	presenting	with	
a	clinical	diagnosis	of	POD.	Exclusion	criteria	were	planned	medical	
treatment	with	 topical	metronidazole,	 erythromycin,	pimecrolimus	
or	oral	tetracycline.	There	was	no	screening	or	washout	phase.
A	50	g	tube	of	the	skin	care	cream	containing	the	TRPV1‐inhibitor	
4‐t‐butylcyclohexanol	cream	(Eucerin	UltraSENSITIVE®,	Beiersdorf	
AG)	was	provided	to	the	patients,	who	were	 instructed	to	apply	 it	
twice	 daily.	 The	 cream's	 ingredients	 are	water,	 squalene,	 glycerin,	
pentylene	glycol,	methylpropanediol,	 tapioca	starch,	arginine	HCL,	
cetearyl	 alcohol,	4‐t‐butylcyclohexanol	 (Trans‐Isomer),	 ammonium,	
acryloyldimethyl‐taurate/VP	 copolymer,	 sodium	carbomer	 and	 ca‐
prylyl	glycol.	Patients	were	not	allowed	to	use	any	other	topical	cos‐
metic	or	medicated	drug	on	the	face,	except	for	the	study	cream.
The	 study	consisted	of	 an	enrollment	visit,	 a	 control	 visit	 after	
4	weeks	and	a	final	visit	after	8	weeks.	A	second	tube	was	provided	
at	the	week‐4	visit,	and	tubes	were	weighed	at	week	4	and	week	8	to	
assess	use	of	the	cream.	A	total	of	two	patients	received	a	third	tube	
of	cream	since	two	tubes	did	not	suffice	 for	 the	treatment	period.	
The	first	visit	included	a	standardized	set	of	questions	for	age,	sex,	
personal	history	of	allergic	rhinoconjunctivitis,	bronchial	asthma	or	
atopic	dermatitis,	known	allergies,	POD	duration	and	previous	use	of	
topical	steroids	or	any	other	treatments.	All	three	visits	consisted	of	
a	physical	examination,	a	documentation	of	clinical	findings	and	ad‐
verse	events,	POD	severity	index	(PODSI),	subjective	POD	severity	
numeral	rating	scale	 (NRS	10)	and	dermatological	 life	quality	 index	
(DLQI)	scores.	Patients	were	additionally	examined	for	objective	skin	
physiology	parameters	with	Tewameter®	for	TEWL,	Corneometer® 
for	stratum	corneum	hydration	(SCH),	pH	meter®	for	pH,	Mexameter® 
for	erythema,	Sebumeter®	for	sebum	level	and	Cutometer®	for	skin	
firmness	 (depth	 of	 skin	 suction,	 in	mm)	 and	 elasticity	 (relationship	
between	 firmness	and	ability	of	 skin	 to	 return	 to	original	position,	
expressed	as	a	percentage).	All	devices	are	a	product	from	Courage‐
Khazaka	Electronic.	All	parameters	were	measured	on	the	affected	
perioral	area	in	addition	to	the	forehead	and	cheek	as	control	areas.
The	study	protocol	was	reviewed	by	the	ethics	committee	of	the	
university	faculty	and	all	participants	provided	written‐informed	con‐
sent.	This	study	was	conducted	in	compliance	with	the	International	
Conference	 on	 Harmonized	 Tripartite	 Guidelines	 for	 Good	 Clinical	
Practice	1996,	Directive	91/507/EEC,	the	Rules	Governing	Medicinal	
Products	in	the	European	Community,	and	the	Declaration	of	Helsinki.
F I G U R E  1  Clinical	improvement	of	perioral	dermatitis	using	a	cosmetic	cream.	First	patient	with	moderate	perioral/periocular	dermatitis	
(POD);	A,	before	(PODSI	3)	and	(B)	after	8	wk	of	treatment	(PODSI	0.5)	with	cream.	Second	patient	with	moderate	POD;	C,	before	(PODSI	4)	
and	(D)	after	8	wk	of	treatment	(PODSI	1)	with	cream
(A)
(B) (C) (D)
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2.2 | Efficacy evaluation
Our	predefined,	primary	endpoint	was	to	check	for	a	significant	im‐
provement	in	the	objective	signs	of	POD	with	the	perioral	dermatitis	
severity	index	(PODSI)	after	4	weeks	(Figure	1).	The	PODSI	repre‐
sents	the	sum	of	three	individual	objective	scores	for	erythema,	pap‐
ules,	and	scaling	graded	from	0	(none)	to	3	(severe)	resulting	in	a	total	
PODSI	score	of	0	to	9.10	Secondary	efficacy	variables	included	single	
items	of	the	PODSI	score,	the	subjective	severity	assessed	with	NRS	
10,	DLQI,	and	skin	physiological	parameters	(TEWL,	SCH,	erythema,	
pH,	sebum	level,	and	elasticity).
2.3 | Adverse events
Adverse	 events	 were	 recorded	 using	 the	 Medical	 Dictionary	 for	
Regulatory	Activities	(MedDRA)	system	during	each	visit,	including	
their	duration	and	severity	grade	(mild,	moderate,	or	severe).
2.4 | Statistical analysis
Efficacy	data	analysis	was	performed	for	the	intent‐to‐treat	popula‐
tion.	The	data	are	presented	as	the	mean	together	with	the	standard	
deviations.	 A	Wilcoxon	 signed‐rank	 test	with	 1‐tailed	P‐value	was	
used	 for	 the	 confirmatory	 analysis	 comparing	 treatment	 response	
and	skin	barrier	function	changes.	The	percentage	change	from	base‐
line	was	summarized	at	each	timepoint.	All	statistics	were	calculated	
using	the	GraphPad	Prism	5	Software	(GraphPad	Software	Inc),	and	
visualization	 of	 data	 using	 graphs	 was	 performed	 using	Microsoft	
Excel.
3  | RESULTS
3.1 | Patient characteristics
Forty‐eight	 patients	 (42	 women	 and	 6	 men)	 with	 a	 mean	 age	 of	
42.4	years	(19‐81	years)	were	enrolled	in	the	study,	and	42	patients	
completed	the	treatment	period.	Reasons	for	discontinuation	were	
noncompliance	in	one	patient,	 inability	to	schedule	the	control	ap‐
pointment	in	one	patient,	worsening	of	the	perioral	dermatitis	in	one	
patient,	and	no‐show	of	three	further	patients.
One‐third	of	the	patients	(35%)	had	an	atopic	diathesis;	13	pa‐
tients	(27%)	had	a	history	of	allergic	rhinoconjunctivitis,	three	pa‐
tients	(6%)	had	a	history	of	bronchial	asthma	and	five	patients	(10%)	
had	a	history	of	atopic	dermatitis.	The	duration	of	POD	ranged	from	
a	minimum	of	1	week	to	a	maximum	of	10	years.	Most	patients	re‐
ported	regular	and	extensive	use	of	facial	skin	care	products	and/
or	make‐up	for	months	and	years	before	the	beginning	of	the	study.
Out	of	the	48	recruited	patients,	22	had	a	history	of	steroid	use.	
Many	readily	received	other	medical	treatments	before	study	enroll‐
ment;	topical	antibiotics,	pimecrolimus,	or	metronidazole.	A	minority	of	
the	patients	had	been	treated	with	oral	tetracyclines	or	tried	zero	ther‐
apy.	The	average	amount	of	cream	used	was	30.93	g	in	the	first	4	weeks	
of	treatment,	and	31.77	g	were	used	during	the	second	4‐week	period.
3.2 | Treatment efficacy
The	mean	PODSI,	 the	primary	endpoint,	was	significantly	reduced	
(P	<	.0001)	from	4.71	±	1.37	to	2.83	±	1.75	after	4	weeks.	A	further	
significant	PODSI	reduction	(P	<	.0001)	to	1.42	±	1.36	was	observed	
F I G U R E  2  Change	of	the	objective	
signs	of	perioral	dermatitis.	Change	in	the	
objective	signs	of	POD	during	8	wk	of	
topical	skin	care	cream	treatment	in	42	
patients.	A,	Change	in	the	PODSI	score,	
(B)	change	of	the	erythema	component	
of	PODSI,	(C)	change	in	the	papular	
component	of	PODSI,	(D)	change	in	
the	squamous	component	of	PODSI.	
***Significance	value	of	P < .0001
(A) (B)
(C) (D)
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after	the	second	4	weeks.	All	three	PODSI	elements	showed	a	highly	
significant	 reduction	 over	 the	 course	 of	 8	 weeks	 as	 well;	 scaling	
showed	the	highest	reduction	(Figure	2).
The	 subjective	 aspects	 of	 POD	 also	 improved	 significantly	
during	 the	 trial	 period.	 The	 mean	 subjective	 disease	 severity	
on	a	 scale	 from	0	 to	10	 (NRS	10)	decreased	 from	6.74	±	1.93	 to	
4.51	 ±	 2.61	 after	 4	weeks	 (P	 <	 .0001)	 and	 then	 to	 a	 final	 score	
of	2.74	±	2.35	after	four	more	weeks.	As	for	DLQI,	the	reduction	
was	also	highly	significant	(P	<	.0001);	during	the	first	4	weeks,	it	
changed	from	10.07	±	5.21	to	5.10	±	4.89	and	to	2.19	±	2.94	after	
the	second	4	weeks	(Figure	3).
3.3 | Skin physiological examination
TEWL	 remained	 unchanged	 in	 the	 first	 4	 weeks,	 changing	 from	
29.36	 ±	 11.98	 to	 29.21	 ±	 12.61	 (P	 =	 .3308),	 and	 then	 decreased	
to	 25.45	 ±	 9.98	 showing	 statistical	 significance	 (P	 =	 .0280)	 in	 the	
second	4	weeks.	The	most	statistically	significant	change	occurred	in	
the	stratum	corneum	hydration,	which	increased	in	the	first	4	weeks	
from	39.35	±	11.75	 to	49.11	±	12.23	 (P	<	 .0001).	After	 four	more	
weeks,	it	remained	stable	to	48.81	±	10.47	without	statistical	signifi‐
cance	(P	=	.4061).	Erythema	decreased	over	the	8	weeks	period	from	
430.20	±	90.50	to	406.90	±	87.85,	showing	a	low	statistical	signifi‐
cance	(P	=	.0178).	All	skin	pH	values	were	within	normal	range;	how‐
ever,	they	decreased	from	5.64	±	0.56	to	5.41	±	0.45	with	statistical	
significance	(P	=	.0016)	after	4	weeks	and	remained	almost	constant	
after	8	weeks	with	a	value	of	5.48	±	0.53	(P	=	.0936).	Finally,	sebum	
level,	skin	elasticity,	and	firmness	did	not	significantly	change	over	
the	treatment	period.	(Figure	4).
3.4 | Subgroup analyses
A	 correlation	 quotient	 R2	 =	 0.02271	 between	 the	 amount	 of	
cream	used	and	PODSI	improvement	was	determined	(Figure	5A),	
F I G U R E  3  Change	in	the	subjective	
symptoms	of	perioral	dermatitis.	Change	
in	the	subjective	symptoms	of	POD	during	
8	wk	of	topical	skin	care	cream	treatment	
in	42	patients.	A,	Change	in	the	overall	
disease	severity	perception	(numerical	
rating	scale	(NRS)),	(B)	change	in	the	
dermatology	life	quality	index	(DLQI).	
***Significance	value	of	P < .0001
(A) (B)
F I G U R E  4  Skin	physiological	changes	during	8‐wk	treatment.	Change	in	the	different	physiological	parameters	of	the	skin	during	8	wk	
of	topical	skin	care	cream	treatment	in	42	patients.	A,	Change	in	the	TEWL	measured	using	Tewameter®,	(B)	change	of	the	stratum	corneum	
hydration	measured	using	Corneometer®,	(C)	change	in	the	pH	measured	using	pH	meter®,	(D)	change	of	the	erythema	measured	using	
Mexameter®,	(E)	change	of	the	sebum	level	measured	using	Sebumeter®,	(F)	change	in	the	skin	elasticity	measured	using	Cutometer®,	(G)	
change	in	the	skin	firmness	measured	using	Cutometer®.	*Significance	value	of	P	<	.05,	**significance	value	of	P	<	.01,	***significance	value	
of	P	<	.0001,	ns:	not	significant
(A) (B) (C)
(E) (F) (G)
(D)
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without	 statistical	 significance.	 Another	 correlation	 was	 tested	
between	 POD	 duration	 and	 treatment	 response.	 A	 quotient	
R2	 =	 0.0002048	 was	 detected	 without	 statistical	 significance	
(Figure	5B).
Atopic	 patients	 were	 compared	 to	 nonatopic	 ones.	 After	
8	weeks,	PODSI	mean	relative	change	showed	an	83.05%	decrease	
with	atopy	and	65.96%	without	atopy.	A	P‐value	of	.0381	with	low	
statistical	significance	was	determined	(Figure	5C).
Male	patients	were	compared	to	females.	PODSI	mean	relative	
change	 resulted	 in	 61.19%	 decrease	 with	males	 and	 72.14%	with	
females.	A	P‐value	of	.0781	was	determined	yet	without	statistical	
significance	(Figure	5D).
3.5 | Adverse events
The	cream	was	well	 tolerated	by	all	patients.	One‐third	of	 the	pa‐
tients	complained	of	a	mild	worsening	of	skin	tenderness	and	ery‐
thema	in	the	first	week	of	treatment.
4  | DISCUSSION
According	to	our	study	results,	the	disease	course	of	POD	improved	
over	 8	weeks	 both	 objectively	 (PODSI)	 and	 subjectively	 (NRS	 10,	
DLQI)	with	high	statistical	significance.	The	TEWL,	SCH,	erythema,	
and	pH	all	showed	improvement	at	the	end	of	the	treatment	period.	
Subgroup	analyses	pointed	out	an	increased	treatment	response	in	
atopic	POD	patients,	and	a	trend	when	using	more	cream	or	in	fe‐
male	patients.	No	important	correlation	was	found	with	medical	his‐
tory	of	POD	before	the	study.
Objective	clinical	score	 improvement	using	PODSI	was	the	pri‐
mary	endpoint	to	determine	clinical	response.	PODSI	changes	over	
the	course	of	4	weeks	and	then	of	8	weeks	clearly	prove	that	the	clini‐
cal	signs	of	POD	improved.	The	subjective	scores	further	support	the	
clinical	improvement	of	disease,	since	patients	had	fewer	complaints	
and	 expressed	 relief	 in	 the	 disease's	 psychological	 burden	 under	
therapy.	Other	POD	therapies	were	also	previously	established;	top‐
ical	erythromycin,	 topical	metronidazole,	and	systemic	 tetracycline	
F I G U R E  5  Subgroup	analyses.	A,	Correlation	between	mean	PODSI	relative	change	&	amount	of	cream	used.	B,	Correlation	between	
mean	PODSI	relative	change	and	POD	duration	before	study	enrollment.	C,	Subgroup	comparison	of	mean	PODSI	relative	change	between	
atopic	and	nonatopic	patients	according	to	medical	history.	D,	Subgroup	comparison	of	mean	PODSI	relative	change	between	male	and	
female	patients
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all	seem	to	have	positive	effects	on	the	disease	course.	Systemic	tet‐
racycline	shows	a	higher	efficacy	than	the	two	other	treatments	and	
is	thus	reserved	for	more	severe	cases.11,12	Efficacy	of	zero	therapy	
has	not	been	investigated	yet.	The	possible	side	effects	that	patients	
might	develop	from	antibiotic	use,	and	the	concern	related	to	bac‐
terial	resistance,	do	not	support	the	use	of	antibiotics	in	POD	in	the	
long‐term.	 Appropriate	 skin	 care	 can	 thus	 be	 used	 long‐term	 and	
serve	as	a	promising	topical	therapy	option	for	POD.
The	 improved	 values	 of	 TEWL,	 stratum	 corneum	hydration,	 pH	
and	erythema	show	an	improvement	of	the	barrier	function	and	a	suc‐
cessful	treatment	response.	The	measured	values	of	this	study	were	
constantly	compared	to	normal	reference	ranges	determined	by	the	
company	providing	the	devices.	These	predetermined	data	are	mea‐
sures	 of	 a	 healthy,	 nonlesional	 skin	 under	 reproducible	 conditions	
(temperature	and	humidity).	Skin	physiology	devices	play	an	important	
role	in	dermatological	research	and	help	to	counteract	clinician's	bias.
Based	on	clinical	experience,	it	is	known	by	now	that	zero	therapy	
is	not	well	accepted	by	patients	suffering	from	POD.	In	reality,	asking	
patients	to	refrain	from	using	all	their	cosmetic	products	and	not	rec‐
ommending	a	specific	therapy	 lead	to	compliance	 issues,	especially	
due	to	the	initial	exacerbation	phase.5	Thus,	engaging	patients	to	use	
a	 skin‐soothing	 cream	 containing	 4‐t‐butylcyclohexanol	 functions	
simultaneously	 as	 a	psychological	 support	 and	a	biologically	 active	
therapy.	Instead	of	overhydrating	the	skin	and	re‐entering	the	hydra‐
tion‐dryness	vicious	circle,	physicians	should	develop	a	trustful	doc‐
tor‐patient	 relationship	 and	deliver	 clear	 instructions	 regarding	 the	
amount	and	frequency	of	cream	used.13	On	the	molecular	level,	TRPV	
receptors	are	known	to	activate	pain	perception	under	inflammatory	
conditions	in	the	skin,	since	they	are	widely	distributed	in	different	
components	of	the	skin	such	as	nerves	and	epithelial	cells.14,15	Firstly,	
ameliorating	 symptoms	 of	 POD	 patients	 is	 a	 substantial	 target	 of	
therapy	and	secondly,	the	subjective	disease	improvement	noted	by	
patients	leads	to	a	higher	compliance	and	remission	rate.
Influencing	 factors	 of	 treatment	 response	 were	 investigated	
by	 subgroup	 analysis.	 Patients	 with	 an	 atopic	 history	 responded	
significantly	 better	 to	 the	 treatment,	 whereas	 all	 other	 subgroup	
analyses	 showed	 trends	 but	 gave	 insignificant	 results.	 It	might	 be	
hypothesized	that	the	observed	results	are	caused	by	an	increased	
cutaneous	damage	at	baseline,	because	women	use	cosmetic	prod‐
ucts	more	excessively	than	men	do,	and	atopic	patients	readily	have	
subclinical	inflammation	and	increased	TEWL.
Our	unblinded,	single‐armed,	prospective	trial	could	have	been	
designed	differently	by	including	a	control	group	of	patients	using	a	
vehicle	 formulation	without	4‐t‐butylcyclohexanol	 and	by	blinding	
the	 two	 groups.	 It	 would	 have	 answered	 different	 questions	 and	
warranted	further	investigations.
The	skin	physiological	parameters	which	were	measured	under	
standardized	and	reproducible	conditions	with	calibrated	and	sen‐
sitive	devices	correspond	 to	 the	clinical	 improvement	under	 treat‐
ment,	thus	drawing	a	comprehensive	picture	overall.
To	sum	up,	this	study	provides	evidence	for	the	clinical	efficacy	
of	a	skin	care	cream	with	a	TRPV1	inhibitor	as	an	active	ingredient	
in	 POD	 treatment.	 Objective,	 subjective	 POD	 scores	 and	 skin's	
physiological	parameters	clearly	improved	during	the	8‐week	treat‐
ment	 period.	 A	 4‐t‐butylcyclohexanol	 cream	 could	 be	 a	 clinically	
useful	treatment	option	for	POD,	especially	due	to	the	absence	of	
side	effects	and	the	lack	of	limitations	in	the	duration	of	treatment.
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